NASDAQ:CRVO CervoMed Q4 2025 Earnings Report $2.94 -0.18 (-5.77%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$2.94 0.00 (-0.17%) As of 06/5/2026 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast CervoMed EPS ResultsActual EPS-$0.88Consensus EPS -$0.79Beat/MissMissed by -$0.09One Year Ago EPSN/ACervoMed Revenue ResultsActual Revenue$0.01 millionExpected Revenue$0.84 millionBeat/MissMissed by -$834.27 thousandYoY Revenue GrowthN/ACervoMed Announcement DetailsQuarterQ4 2025Date3/13/2026TimeBefore Market OpensConference Call DateFriday, March 13, 2026Conference Call Time7:00AM ETUpcoming EarningsCervoMed's Q2 2026 earnings is estimated for Friday, August 14, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) CervoMed Earnings HeadlinesPathfinder Cell Therapy (OTCMKTS:PFND) & CervoMed (NASDAQ:CRVO) Head-To-Head SurveyJune 3, 2026 | americanbankingnews.comCervoMed Inc. (NASDAQ:CRVO) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 31, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.June 7 at 1:00 AM | InvestorPlace (Ad)CervoMed Inc. Reports Advancements in Neflamapimod Development for Dementia with Lewy Bodies and Announces Phase 3 Trial PlansMay 18, 2026 | quiverquant.comQCervoMed Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 18, 2026 | globenewswire.comCervoMed Insider Trading Activity | NASDAQ:CRVO | BenzingaMay 14, 2026 | benzinga.comSee More CervoMed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CervoMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CervoMed and other key companies, straight to your email. Email Address About CervoMedCervoMed (NASDAQ:CRVO), a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.View CervoMed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?A Lulu of a Miss Sends Lululemon to New Lows—Look Out BelowFive Below Down 12% Post Earnings—Is the Selloff Overdone?IREN's 800MW Bet Flips the AI Power SwitchBuy the Dip? Broadcom's AI Moat Is Wider Than EverCrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?The Market Has Ollie’s Bargain Outlet Completely Wrong Upcoming Earnings Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
